Meglumine antimoniate description
Jump to navigation
Jump to search
| Meglumine Antimoniate |
|---|
| GLUCANTIM® WHO Prescribing Information |
| Description |
| Indications and Usage |
| Contraindications |
| Warnings and Precautions |
| Adverse Reactions |
| Dosage and Administration |
| How Supplied |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Description
Pentavalent antimony compounds with leishmanicidal activity, but which are not effective against free flagellated forms in vitro. It is uncertain whether they have selective activity against intracellular forms, or whether small amounts are converted intracellularly into a potent trivalent inhibitor of the parasite’s glycolytic enzymes.
Since they are poorly absorbed and highly irritant to the gastrointestinal tract they must be administered parenterally or by local injection. Over 80% of the dose is excreted unchanged in the urine within 6 hours.[1]
References
Adapted from the FDA Package Insert.